BIO Bio-Rad Laboratories
$358.90 -2.34%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Point at or drag across the chart to read a day. EOD data.
1D
-2.34%
YTD
+18.50%
P/E
9.56
P/B
1.1
ROE
14.1%
Div yield
—
Beta
0.7
Market cap
$9.8B
RSI (14)
43
Next earnings
Feb 10, 2027
Same sector · Health Care
Compare BIO with NVO and JNJ →Follow BIO in the AlfaCat app
Watchlist, price and earnings alerts, the chart offline. Free, no account, no ads.
The economy behind it · United States
Economy this week on BullDozer →GDP, % on year
2.1
Q3 2026
Inflation, %
3.7
Sep 2026
Unemployment, %
3.9
Oct 2026
10-yr yield, %
5.13
Oct 2026
From BullDozer, our sister site for country statistics (open sources: OECD, IMF, Eurostat, ILO). Full United States profile →
Previous session
close of Nov 20, 2026 · EOD, no live order bookOpen
$364.34
Close
$358.90
Day high
$369.44
Day low
$353.31
Volume
182K
Latest headlines
Refrigerated Incubators - Global Strategic Business Report 2026: Capitalize on $209.9M Market Expansion with Thermo Fisher, Eppendorf, Binder, Bio-Rad and Memmert
Yahoo Finance · Nov 20
Global Oral Cancer Rapid Test Kits Market to Hit $1.2 Billion by 2032 - Roche, Beckman Coulter, Bio-Rad, OraSure, and Insilixa Battle for Share
Yahoo Finance · Nov 20
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Yahoo Finance · Nov 13
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck
Yahoo Finance · Nov 12
Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition
Yahoo Finance · Nov 12
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
Yahoo Finance · Nov 11
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Nov 4, 2026 View → 8-K Nov 4, 2026 View → 10-Q Aug 4, 2026 View → 8-K Aug 4, 2026 View → 10-Q Apr 30, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell BIO. Try it in the Lab to size a position and see the risk.